PER Percheron Therapeutics Ltd
- 0.009
- +0.001+12.50%
Percheron Therapeutics Ltd News
Percheron Therapeutics Ltd: Topline Six-Month Results From Phase IIb Study of Avicursen
Percheron Therapeutics Ltd: Trading Halt
Percheron Therapeutics Ltd: Reorganisation of US Quoted Securities
Percheron Therapeutics Ltd: Clinical Trial Update
Percheron Therapeutics Ltd: Annual General Meeting - Chair's Address
Percheron Therapeutics Ltd: Percheron launches post-trial access program
Percheron Therapeutics Ltd: Percheron Holds International Advisory Boards
Percheron Therapeutics Ltd: Proposed issue of securities - PER
Percheron Therapeutics Ltd: Proposed issue of securities - PER
Percheron Therapeutics Ltd: $13.0 million Institutional Placement
Percheron Therapeutics Ltd: Trading Halt
Percheron Therapeutics Ltd: Change of Company Auditor
Percheron Therapeutics Ltd: Completion of avicursen (ATL1102) toxicology study
Percheron Therapeutics Ltd: ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy
Percheron Therapeutics Ltd: Notice of date of AGM and other relevant dates
Percheron Therapeutics Ltd: Appendix 4G and Corporate Governance Statement
Percheron Therapeutics Ltd: Quarterly Activities Report and Appendix 4C
Percheron Therapeutics Ltd: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
Percheron Therapeutics Ltd: Phase IIb study of ATL1102 in DMD completes recruitment
Percheron Therapeutics Ltd: Preliminary Results of 9 Month Toxicology Study of ATL1102
No Data